| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d5d77f66f59d53a3906f98ab95a55ef |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
1998-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a936024a7e99e687679907e4b232bf4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25a1139c53769edd8a7fafb368de83a6 |
| publicationDate |
1999-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H1171298-A |
| titleOfInvention |
Pharmaceutical and diagnostic compositions containing neuropeptide antagonists |
| abstract |
(57) [Summary] (Modified) [PROBLEMS] To provide a method of using a neuropeptide antagonist. SOLUTION: The polypeptide having the features of 1) to 6). 1) A single-chain glycopolypeptide rich in mannose side chains. 2) Selective binding to bombesyl-type polypeptide. 3) molecular weight 75-85 kDa. 4) Isoelectric point 6.4-6.9. 5) The molecular weight of the core protein obtained using endo-β-N-glucosaminidase from Flavobacterium meningosepticum is about 42 Kd. 6) 3-15 mM, preferably 5-10 mM Mg ++ The equilibrium dissociation constant at 15 ° C. was 1.9 × 10 −10 M by kinetic analysis using a membrane preparation obtained by disrupting Swiss 3T3 cells in an aqueous medium containing 2.1 × 10 −10 M by coupling). |
| priorityDate |
1988-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |